The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

被引：0
|
作者：
Van Cutsem, E. [1 ]
Lang, I [2 ]
D'haens, G. [3 ]
Moiseyenko, V [4 ]
Zaluski, J. [5 ]
Koehne, C. [6 ]
Folprecht, G. [7 ]
Tejpar, S. [1 ]
Shparyk, Y. [8 ]
Schlichting, M. [9 ]
Kisker, O. [9 ]
Stroh, C. [9 ]
Rougier, P. [10 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Orszagos Onkol Intezet, Budapest, Hungary
[3] Imelda Ziekenhuis, Bonheiden, Belgium
[4] NN Petrov Oncol Res Inst, St Petersburg, Russia
[5] Weikopolskie Centrum Onkol, Poznan, Poland
[6] Klinikum Oldenburg, Oldenburg, Germany
[7] Univ Klin Carl Gustav Carus, Dresden, Germany
[8] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[9] Merck Serono, Darmstadt, Germany
[10] Hop Ambroise Pare, Boulogne, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [21] Cetuximab plus Xeliri versus cetuximab plus xelox as first-line treatment of patients with metastatic colorectal cancer (MCRC): A randomised trial of the German Aid CRC study group
    Heinernann, V
    Fischer, Von Weikersthal L.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Hass, H.
    Weiss, J.
    Dietzfelbinger, H.
    Moosmann, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 13 - 13
  • [22] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [23] Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status
    Bokemeyer, C.
    Kohne, C.
    Rougier, P.
    Stroh, C.
    Schlichting, M.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
    Beslija, S.
    Koza, I.
    Ocvirk, J.
    Ciuleanu, T.
    Kurteva, G.
    Papamichael, D.
    Vrbanec, D.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
  • [25] UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL
    Rougier, P.
    Janciauskiene, R.
    Paramonov, V
    Shparyk, Y.
    Gustavsson, B.
    Wagnerova, M.
    Gorbunova, V
    Utracka-Hutka, B.
    Celik, I
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 15 - 15
  • [26] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [27] Analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC)
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, Fischer L.
    Moosmann, N.
    Kirchner, T.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 226 - 226
  • [28] First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study
    Sastre, Javier
    Gravalos, Cristina
    Rivera, Fernando
    Massuti, Bartomeu
    Valladares-Ayerbes, Manuel
    Marcuello, Eugenio
    Manzano, Jose L.
    Benavides, Manuel
    Hidalgo, Manuel
    Diaz-Rubio, Eduardo
    Aranda, Enrique
    ONCOLOGIST, 2012, 17 (03): : 339 - 345
  • [29] Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
    Folprecht, G.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Zubel, A.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345